The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Synairgen (SNG): Corp
Positive Pharmaxis LOXL2 Phase I data
Pharmaxis announced positive results from the Phase I trial for the second of its Lysyl Oxidase Like 2 (LOXL2) inhibitor
compounds being developed to treat fibrotic diseases such as Non‐Alcoholic Steatohepatitis (NASH) and Idiopathic
Pulmonary Fibrosis (IPF). This followed positive Phase I results for its first LOXL2 inhibitor. Synairgen retains a 17%
carried financial interest in this programme. Given that Pharmaxis plans to license LOXL2, we expect Synairgen to
receive a share of any upfront payment. We leave our target price unchanged at 54p. This will rise on the successful
completion of a licensing deal, which we now expect in 2019.
There is little free float of this share... A unqiue share with great growth potential and possibly replicable in many territories..Hence I believe the gap between Bid and Ask...
The sheer number of Sectors covered by Keystone should give it a good cushion against any economic downturn... and with Brexit / non Brexit on the agenda .. Legal and related advice will be in great demand.and Keystone should be a beneficiary..
Sectors
Aviation
Education
Financial Services
Food & Beverage
Healthcare
High-Net Worth Family Office
Hotels, Hospitality & Leisure
In-House Legal
Law Firm Support
Marine & Shipping
Media
Private Individual
Professional Practices
Property Development
Retail
Satellite, Space & Communications
Sports
Technology & Telecoms
14/11/2018 Pharmaxis Bulletin (20:47)
Positive Results of Phase 1 Clinical Trial for Second LOXL2 Inhibitor Compound
Pharmaceutical company Pharmaxis (ASX: PXS) today announced positive results from the Phase 1 clinical trial for the second of its Lysyl Oxidase Like 2 (LOXL2) inhibitor compounds being developed to treat fibrotic diseases such as Non‐Alcoholic Steatohepatitis (NASH) and Idiopathic Pulmonary Fibrosis (IPF).
Repeating the positive results seen in the Phase 1 trial of the first inhibitor compound announced on 10 October 2018, the excellent drug like properties demonstrated in earlier pre-clinical testing were confirmed. There were no adverse safety findings in either the first or second stages of the study and the pharmacokinetic profile showed the expected dose related increases in exposure.
Significant target engagement of the LOXL2 enzyme by both compounds has now been demonstrated in blood serum for a full 24 hours from a single dose over a 14-day period, with the second compound achieving more than 85% inhibition over 24 hours from a 100mg daily dose, achieving the target for this program.
Pharmaxis CEO Gary Phillips said, “Several large pharma companies are interested in the Pharmaxis program where both of our LOXL2 inhibitors have now successfully completed phase 1 studies and demonstrated a best in class profile with 24-hour inhibition of the target enzyme from a single daily dose. In a further significant scientific advancement we have also managed to underline the relevance of the program to potential partners by using our proprietary research tools to confirm that our compounds directly inhibit the activity of the raised levels of LOXL2 seen in diseased tissue from NASH and IPF animal models.”
Phillips continued, “The only remaining elements necessary to finalise the data package that companies are now conducting diligence on, are the 3-month toxicity studies on both compounds which are due to report later this quarter. This is slightly delayed versus initial expectations due to the availability of time slots at the contract organisations we use but successful 3-month studies will significantly enhance the LOXL2 program. Following the completion of the data package, Pharmaxis intends to conduct a final series of scientific briefings to potential partners before moving to commercial partnering discussions to secure a comprehensive licensing agreement in 2019.”
According to the London Stock Exchange the 100000 trade declared today at 16.5 is described as Large in Scale Deferral (LRGS)..
My view is that this transaction has been deferred from the time of the SNG share placing (End Sept / Oct 18) or thereafter.. The 100000 shares might even be a purchase by somebody wishing to build or add to an existing stake..
A sale of 100000 shares in one tranch would have caused a major plummet of the SNG share price...
RichThe Newbie is I believe correct regarding the trade feeds...
The full impact of where those ( Sept placing) shares not taken up by the major shareholders went to is still to emerge.. Watch for some interesting new names to appear on the SNG share register sooner rather than later..
Extract from todays Quaterly published update..
Partnering plan for LOXL2 program Large pharma is interested in the Pharmaxis LOXL2 program as it is one of the very few truly anti‐fibrotic mechanisms in clinical development. The excellent pharmacokinetic parameters and
the significant and long lasting inhibition of the target LOXL2 enzyme demonstrated by the program compounds has led to increased interest from major pharmaceutical companies looking for good anti fibrotic programs to acquire.
This quarter the Company expects to complete the data package which a number of potential partners are currently reviewing. Commercial discussions are expected to quickly follow and conclude in 2019
Richard Griffiths, a private investor, now holds 15,391,112 ordinary shares of 1 pence each in the capital of the Company, representing 14.06% of the Company's issued share capital.
An increase of nearly 2 Million shares...
Tonights Presentation slides
http://www.synairgen.com/wp-content/uploads/2018/10/Presentation-4-October-2018.pdf
These shares appear to moving at rocket speed...
Perhaps the presentation , perhaps the Interim Results Presentation ( Sept 2018) has somethong to do with the rise
http://www.keystonelaw-ir.co.uk/archive/presentations/Investor-Presentation-Sep-18.pdf
(Reuters) - Large drugmakers with piles of cash are on the hunt for promising medicines being developed by small companies to treat NASH, a progressive fatty liver disease poised to become the leading cause of liver transplants by 2020.
The eventual market for the complex disease, formally known as Non-alcoholic Steatohepatitis, is forecast to be $20 billion to $35 billion as populations with fatty diets increasingly fall victim to a condition with no approved treatments.
With intense competition and pricing pressure eroding sales of medicines for diabetes, rheumatoid arthritis and other lucrative disease categories, and an already crowded field for developmental cancer drugs, big pharma sees NASH as an enormous new market for future profit that will accelerate a wave of deal making.
Estimates for the prevalence of NASH in nations with fatty diets range from 5 to 20 percent of the population with up to 15 million potentially affected in the United States alone.
Driven by the obesity and diabetes epidemics, the disease guarantees an enormous pool of patients for decades, making it a prime target for deals for promising therapies for NASH and its consequences - advanced fibrosis and liver-destroying cirrhosis. The very early stages of many of the drugs, and the complicated nature of the disease itself, pose risks for drug developers and their investors alike.
But the upside potential is still enticing to Raghuram Selvaraju, managing director and senior healthcare analyst at Rodman and Renshaw. He calls NASH one of the hottest spaces in the healthcare sector.
"We anticipate that there will be more transactions, more licensing deals from big pharma involving emerging biotechnology companies," he said.
from ohisay today on the ADVFN notice Board
Synairgen and Rich retweeted this on Twitter .Worth showing here to.
http://www.proactiveinvestors.co.uk/companies/news/204622
The latest Pharmaxis Investor Presentation is now avaiable (28th Aug 2018)
http://www.pharmaxis.com.au/investor-centre/news/view/investor-presentation-28-august-2018
It is still looking very positive..Q3 / Q4 updates will make very interesting / and hopefully very positive reading
Arix have invested substantially in Pharmaxis .. presumably as they see huge potential in LOXL2 and the Pharmaxis pipeline ... Would it not make sense for them to invest in Synairgen as well for its Interferon B potential ..and then, its only a possibility engineer a merger of Pharmaxis and Synairgen... Thus creating a unique pipeline and a joined up LOXL2 revenue stream for the joint company..Only a thought !
From ohisay on the ADVFN Board 31st July 2018
Just been looking at the Finncap note from June again.
Couple of things FWIW..
1.They have the full unrisked value of SNG0001 (in other words assuming it gets to market) at 175p/share. They have it currently risked at ~ 25% for the present 45p valuation.
2.Their LOXL2 risked valuation rises to 28p from 18p assuming PXS phase 1/toxicity successful results.(I'd expect more derisking if a subsequent partnering deal was done with PXS)
3.Ie giving an overall risked valuation of 73p from the present 63p with potentially more to come from a LOXL farmout..
Quarterly Shareholder Update – June 2018 - PHARMAXIS
Very Positive for LOXL2
hxxp://www.pharmaxis.com.au/assets/Documents/pdf/02018/ASX/2018-07-27-Quarterly-Shareholder-Update-June-2018.pdf?utm_medium=email&utm_campaign=Quarterly%20Update%20-%20June%202018&utm_content=Quarterly%20Update%20-%20June%202018+CID_3ad146408727e05b6c69121104fbbf30&utm_source=Campaign%20Monitor&utm_term=View%20Quarterly%20Update
Partnering plan for LOXL2 program
Large pharma is interested in the Pharmaxis
LOXL2 program as it is one of the very few truly
anti‐fibrotic mechanisms in clinical development
and a number of pharma companies have been
following the progress of the Pharmaxis LOXL2
program for more than two years. At the recent
BIO18 partnering conference in Boston the
Company briefed potential partners on data
emerging from the phase 1 clinical studies and the
formal due diligence process.
Pharmaxis plans to partner the LOXL2 program in
the second half of 2018 after the phase 1 trials
and longer‐term toxicity studies report
Rich.. agree entirely.. The fundementals since the rise to 20p plus haver not changed... There has been no bad news or in fact any news since last week... SNG is a share (In my opinion) with an 12 - 18 month window that hopefully be re-rated consideably as and when the results from both LOXL2 and SNG001 start to appear... Possibly sooner if positive interim updates are received... The Herd / Trader Crowd are after instant profits .. and move on if not fulfilled.. Once we have clensed the share of these short termers.. Long term holders should gain considerably from solid newsflow.
It would be very wrong not to say I am delighted that the market is begining to see the potential of SNG... This share has had a number of ups and downs .. in my view this is to be expected when one is dealing with leading edge scientific discovery.. It has been badly punished on the downs (6p share proce_ and yet is still far away from what I believe could ot might be a full realistic price... Finn Cap have a 63p view on SNG.. this view should change positively and substantially over the coming months...Why? If LOXL2 achieves its Phase 1 goals and achieves the right partner..SNG's 17% stake could be worth ( my own very positive guestimate £1 plus...this is just a view and not a hype at all... then the COPD trial for Interferon B.. Q2 next year will i believe (a personal very positive view and no evidence other than Richard Marsden's comments and interview that it looks positivethat SNG will deliver the goods.. This might be worth at least another £1 per share... ALL my own views and not quoted to hype the price what so ever.. Woodford and CO are in this for a very big return 10 - 20 times their intial investment or more.. I suspect Mr Licht the same..If you are a believer and my comments give my view and it is only a personal view .. try and stay the course.. temptation at prices substantially above current price are likely to come your way... the timescale is not excessive for my thoughts and outcome.. Q2 / Q3 2019... Only you as individula shareholders can decide what course of action and personal outcomes you wish to ssee from your holding in SNG...
Agree entirely TLR2014....A very shrewd investor. is Leonard Licht..
SNG was today informed that Leonard Licht, a private investor, now holds 7,700,000 ordinary shares of 1 pence each in the capital of the Company through his Choice Bespoke SIPP.
This represents 8.48% of the total voting rights of the Company.
From the ADVFN Board
http://www.proactiveinvestors.co.uk/companies/stocktube/9664/synairgen-says-its-drug-well-tolerated-in-phase-ii-trial-9664.html
Marsden on COPD ..- coming days or weeks for the biomarker data to be released .Next two weeks then ?
If that's good that 14/15p resistance level will be well and truly history .